lung cancer(5) COVID-19(5) Extended(4) Cohort(4) Cell(4) Treatment(4) COVID-19 pandemic(4) survival(4) Patient(4) Retrospective analysis(3) Frequency(3) Standard dose(3) clinically(3) coronavirus(3) reduction in(3) adverse event(3) Dosing(3) Dose adaptation(3) stage III(3) resulting(3) comparable(3) in both groups(3) inhibitor(3) Safe(3) Pembrolizumab(3) dose reduction(3) receiving(3) therapy(3) interval(3) immune(3)